{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:04:48Z","timestamp":1772147088097,"version":"3.50.1"},"reference-count":23,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,4,9]]},"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>A 47-year-old previously healthy man presented with acute moderate flank pain. Evaluation revealed left renal cell carcinoma, with inferior vena cava tumour thrombus invasion. Patient had no significant history or risk factors to pre-dispose him to genitourinary cancers. Surgery was deemed to not be appropriate due to distant metastases, but patient received targeted molecular therapy and immunotherapy with striking regression of the thrombus.<\/jats:p>","DOI":"10.1136\/bcr-2018-227030","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T16:06:15Z","timestamp":1556035575000},"page":"e227030","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Robust response to nivolumab in patient with renal cell carcinoma inferior vena cava tumour thrombus"],"prefix":"10.1136","volume":"12","author":[{"given":"Joel","family":"Berends","sequence":"first","affiliation":[{"name":"Department of Urology, University of Texas Health, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Gourley","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharam","family":"Kaushik","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"2025082710362021000_12.4.e227030.1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.14735\/amko2018110","article-title":"[Treatment of Metastatic Renal Cell Carcinoma]","volume":"31","author":"Richter","year":"2018","journal-title":"Klin Onkol"},{"key":"2025082710362021000_12.4.e227030.2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13193-011-0114-2","article-title":"IVC Thrombectomy in Renal Cell Carcinoma-Analysis of Out Come Data of 100 Patients and Review of Literature","volume":"3","author":"Kulkarni","year":"2012","journal-title":"Indian J Surg Oncol"},{"key":"2025082710362021000_12.4.e227030.3","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-116439","article-title":"Venous Thromboembolism in Cancer Patients Receiving Immunotherapy","volume":"132","author":"Roopkumar","year":"2018","journal-title":"Blood"},{"key":"2025082710362021000_12.4.e227030.4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12032-018-1147-y","article-title":"Check point inhibitors a new era in renal cell carcinoma treatment","volume":"35","author":"Alsharedi","year":"2018","journal-title":"Med Oncol"},{"key":"2025082710362021000_12.4.e227030.5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.15586\/jkcvhl.2018.102","article-title":"Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives","volume":"5","author":"Ochoa","year":"2018","journal-title":"J Kidney Cancer VHL"},{"key":"2025082710362021000_12.4.e227030.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.002"},{"key":"2025082710362021000_12.4.e227030.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11174.x"},{"key":"2025082710362021000_12.4.e227030.8","doi-asserted-by":"crossref","first-page":"112.e23","DOI":"10.1016\/j.urolonc.2014.11.015","article-title":"Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension","volume":"33","author":"Zargar-Shoshtari","year":"2015","journal-title":"Urol Oncol"},{"key":"2025082710362021000_12.4.e227030.9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0039"},{"key":"2025082710362021000_12.4.e227030.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.02.032"},{"key":"2025082710362021000_12.4.e227030.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-013-1088-1"},{"key":"2025082710362021000_12.4.e227030.12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10147-017-1119-9","article-title":"Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma","volume":"22","author":"Fukuda","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"2025082710362021000_12.4.e227030.13","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2147\/OTT.S158114","article-title":"Role of presurgical targeted molecular therapy in renal cell carcinoma with an inferior vena cava tumor thrombus","volume":"11","author":"Peng","year":"2018","journal-title":"Onco Targets Ther"},{"key":"2025082710362021000_12.4.e227030.14","doi-asserted-by":"crossref","unstructured":"Field CA , Cotta BH , Jimenez J , et al . Neoadjuvant sunitinib decreases inferior vena caval thrombus size and is associated with improved oncologic outcomes: a multicenter comparative analysis. Clin Genitourin Cancer 2019 [Epub ahead of print 30 Jan 2019].doi:10.1016\/j.clgc.2019.01.013","DOI":"10.1016\/j.clgc.2019.01.013"},{"key":"2025082710362021000_12.4.e227030.15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000492723","article-title":"Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus","volume":"101","author":"Cai","year":"2018","journal-title":"Urol Int"},{"key":"2025082710362021000_12.4.e227030.16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CAD.0000000000000627","article-title":"Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus","volume":"29","author":"Terakawa","year":"2018","journal-title":"Anticancer Drugs"},{"key":"2025082710362021000_12.4.e227030.17","doi-asserted-by":"crossref","first-page":"070","DOI":"10.1055\/s-0033-1363845","article-title":"Role of embolization in the treatment of renal masses","volume":"31","author":"Li","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"2025082710362021000_12.4.e227030.18","doi-asserted-by":"crossref","unstructured":"Zielinski H , Syrylo T , Szmigielski S . Chen J , Renal Artery Embolization in Treatment of Renal Cancer with Emphasis on Response of Immune System: Renal Tumor. InTech, 2013:95\u2013108.","DOI":"10.5772\/54116"},{"key":"2025082710362021000_12.4.e227030.19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1159\/000495459","article-title":"Rare case of intracardiac renal cell carcinoma metastasis with response to nivolumab: case report and literature review","volume":"11","author":"Ansari","year":"2018","journal-title":"Case Rep Oncol"},{"key":"2025082710362021000_12.4.e227030.20","doi-asserted-by":"publisher","DOI":"10.1177\/1758834016679942"},{"key":"2025082710362021000_12.4.e227030.21","first-page":"187","article-title":"[Immunotherapy for renal cell carcinoma - current status]","volume":"49","author":"Grimm","year":"2018","journal-title":"Aktuelle Urol"},{"key":"2025082710362021000_12.4.e227030.22","doi-asserted-by":"crossref","unstructured":"Powles T , Albiges L , Staehler M , et al . Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. Eur Urol 2017.doi:10.1016\/j.eururo.2017.11.016","DOI":"10.1016\/j.eururo.2017.11.016"},{"key":"2025082710362021000_12.4.e227030.23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:36:31Z","timestamp":1756316191000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,23]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/bcr-2018-227030"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227030","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}